pubmed.ncbi.nlm.nih.gov

Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity - PubMed

Clinical Trial

Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity

F Greenway et al. Obes Res. 1999 Jul.

Free article

Abstract

Objective: Phenylpropanolamine (PPA) and benzocaine are non-prescription medications approved for treating obesity. The dose of PPA for weight loss is 75 mg/day. PPA has the same chemical similarity to pseudoephedrine that amphetamine has to methamphetamine. Because benzocaine causes weight loss by altering taste and PPA by central appetite suppression, they may induce additional weight loss when combined. These studies explore the safety and efficacy of low-dose PPA, pseudoephedrine, and PPA with benzocaine in causing weight loss.

Research methods and procedures: Study 1 compared PPA 12.5 mg tid with 25 mg tid and placebo in a 6-week trial in 108 obese subjects. Study 2 compared pseudoephedrine 120 mg/day and a placebo in a 12-week trial with 72 obese subjects. Study 3 compared 4 groups of 20 obese subjects using PPA 75 mg/day, benzocaine gum 96 mg/day, PPA with benzocaine gum, and a placebo over 12 weeks.

Results: Both doses of PPA gave twice the weight loss of placebo, but the difference did not reach statistical significance. Pseudoephedrine was no different than placebo in inducing weight loss. The PPA with benzocaine group had more adverse events than the benzocaine group (p = 0.03), the placebo group (p = 0.03), or the PPA group (p = 0.09) without additional weight loss.

Discussion: We conclude that further studies with low-dose PPA for weight loss are indicated, that pseudoephedrine is not effective for weight loss, and that adding benzocaine to phenylpropanolamine increases adverse effects without increasing weight loss.

PubMed Disclaimer

Cited by

In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine.
Munafò A, Frara S, Perico N, Di Mauro R, Cortinovis M, Burgaletto C, Cantarella G, Remuzzi G, Giustina A, Bernardini R. Munafò A, et al. Rev Endocr Metab Disord. 2021 Dec;22(4):1013-1025. doi: 10.1007/s11154-021-09658-w. Epub 2021 May 4. Rev Endocr Metab Disord. 2021. PMID: 33945051 Free PMC article. Review.
Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ. Ioannides-Demos LL, et al. Drugs. 2005;65(10):1391-418. doi: 10.2165/00003495-200565100-00006. Drugs. 2005. PMID: 15977970 Review.
Dietary supplements for obesity.
Bonetti G, Herbst KL, Donato K, Dhuli K, Kiani AK, Aquilanti B, Velluti V, Matera G, Iaconelli A, Bertelli M. Bonetti G, et al. J Prev Med Hyg. 2022 Oct 17;63(2 Suppl 3):E160-E168. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2757. eCollection 2022 Jun. J Prev Med Hyg. 2022. PMID: 36479472 Free PMC article. Review.
Combination drugs for treating obesity.
Greenway FL, Bray GA. Greenway FL, et al. Curr Diab Rep. 2010 Apr;10(2):108-15. doi: 10.1007/s11892-010-0096-4. Curr Diab Rep. 2010. PMID: 20425569 Review.
Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats.
Dostalek M, Hadasova E, Hanesova M, Pistovcakova J, Sulcova A, Jurica J, Tomandl J, Linhart I. Dostalek M, et al. Eur J Drug Metab Pharmacokinet. 2005 Jul-Sep;30(3):195-201. doi: 10.1007/BF03190620. Eur J Drug Metab Pharmacokinet. 2005. PMID: 16250257

Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity - PubMed